The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|October 30, 2022
Dr. Rana McKay on next steps in advanced renal cell carcinoma
Author(s)Urology Times staff
Advertisement
Rana McKay, MD, discusses the next steps needed to advance the treatment paradigm for patients with advanced renal cell carcinoma. McKay is a medical oncologist and associate professor of medicine at the University of California San Diego, Moores Cancer Center.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5